Trial Outcomes & Findings for Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder (NCT NCT01564862)

NCT ID: NCT01564862

Last Updated: 2015-02-05

Results Overview

The DSST assesses relative contributions of speed, memory, executive function and visual scanning. Participants are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time for a total possible score of 0 to 133. Higher scores-correct number of symbols reflects greater objective cognitive functioning. An increase in score represents an improvement in an integrated measure of cognitive function. An Analysis of Covariance (ANCOVA) model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

602 participants

Primary outcome timeframe

Baseline and Week 8

Results posted on

2015-02-05

Participant Flow

Participants took part in the study at 80 investigative sites in Bulgaria, Finland, Germany, Poland, Russia Federation, Ukraine.and the United States from 09 April 2012 to 05 February 2014

Participants with a diagnosis of major depressive disorder were enrolled equally in 1 of 3 treatment groups, once a day placebo, 10 to 20 mg flexible dose of vortioxetine, or 60 mg duloxetine.

Participant milestones

Participant milestones
Measure
Vortioxetine (Lu AA21004)
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Overall Study
STARTED
198
210
194
Overall Study
Received Treatment
196
207
191
Overall Study
COMPLETED
168
176
164
Overall Study
NOT COMPLETED
30
34
30

Reasons for withdrawal

Reasons for withdrawal
Measure
Vortioxetine (Lu AA21004)
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Overall Study
Pretreatment Event or Adverse Event
6
12
6
Overall Study
Major Protocol Deviation
3
3
4
Overall Study
Lost to Follow-up
10
8
6
Overall Study
Voluntary Withdrawal
9
6
8
Overall Study
Lack of Efficacy
1
5
6
Overall Study
Other reason(s)
1
0
0

Baseline Characteristics

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Vortioxetine (Lu AA21004)
n=198 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=210 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=194 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Total
n=602 Participants
Total of all reporting groups
Age, Continuous
44.2 years
STANDARD_DEVIATION 12.21 • n=99 Participants
45.7 years
STANDARD_DEVIATION 11.46 • n=107 Participants
45.0 years
STANDARD_DEVIATION 12.07 • n=206 Participants
45.0 years
STANDARD_DEVIATION 11.90 • n=7 Participants
Age, Customized
≤ 55 years
158 participants
n=99 Participants
164 participants
n=107 Participants
152 participants
n=206 Participants
474 participants
n=7 Participants
Age, Customized
> 55 years
40 participants
n=99 Participants
46 participants
n=107 Participants
42 participants
n=206 Participants
128 participants
n=7 Participants
Sex: Female, Male
Female
135 Participants
n=99 Participants
138 Participants
n=107 Participants
119 Participants
n=206 Participants
392 Participants
n=7 Participants
Sex: Female, Male
Male
63 Participants
n=99 Participants
72 Participants
n=107 Participants
75 Participants
n=206 Participants
210 Participants
n=7 Participants
Race/Ethnicity, Customized
Hispanic or Latino
8 participants
n=99 Participants
7 participants
n=107 Participants
15 participants
n=206 Participants
30 participants
n=7 Participants
Race/Ethnicity, Customized
Non-Hispanic and Non- Latino
90 participants
n=99 Participants
104 participants
n=107 Participants
82 participants
n=206 Participants
276 participants
n=7 Participants
Race/Ethnicity, Customized
Not-Specified
100 participants
n=99 Participants
99 participants
n=107 Participants
97 participants
n=206 Participants
296 participants
n=7 Participants
Race/Ethnicity, Customized
Caucasian (or White, including Hispanic)
169 participants
n=99 Participants
176 participants
n=107 Participants
171 participants
n=206 Participants
516 participants
n=7 Participants
Race/Ethnicity, Customized
Black
28 participants
n=99 Participants
27 participants
n=107 Participants
20 participants
n=206 Participants
75 participants
n=7 Participants
Race/Ethnicity, Customized
Asian
1 participants
n=99 Participants
6 participants
n=107 Participants
1 participants
n=206 Participants
8 participants
n=7 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
0 participants
n=99 Participants
1 participants
n=107 Participants
2 participants
n=206 Participants
3 participants
n=7 Participants
Height
168.2 cm
STANDARD_DEVIATION 9.17 • n=99 Participants
169.7 cm
STANDARD_DEVIATION 9.14 • n=107 Participants
169.0 cm
STANDARD_DEVIATION 9.43 • n=206 Participants
169.0 cm
STANDARD_DEVIATION 9.25 • n=7 Participants
Weight
81.84 kg
STANDARD_DEVIATION 22.068 • n=99 Participants
81.68 kg
STANDARD_DEVIATION 20.965 • n=107 Participants
80.96 kg
STANDARD_DEVIATION 20.316 • n=206 Participants
81.50 kg
STANDARD_DEVIATION 21.099 • n=7 Participants
Body Mass Index (BMI)
28.86 kg/m^2
STANDARD_DEVIATION 7.334 • n=99 Participants
28.39 kg/m^2
STANDARD_DEVIATION 7.312 • n=107 Participants
28.27 kg/m^2
STANDARD_DEVIATION 6.354 • n=206 Participants
28.51 kg/m^2
STANDARD_DEVIATION 7.018 • n=7 Participants
Smoking Classification
Never Smoked
95 participants
n=99 Participants
109 participants
n=107 Participants
105 participants
n=206 Participants
309 participants
n=7 Participants
Smoking Classification
Current Smoker
73 participants
n=99 Participants
68 participants
n=107 Participants
56 participants
n=206 Participants
197 participants
n=7 Participants
Smoking Classification
Past Smoker
30 participants
n=99 Participants
33 participants
n=107 Participants
33 participants
n=206 Participants
96 participants
n=7 Participants
Alcohol Consumption
Never
89 participants
n=99 Participants
84 participants
n=107 Participants
87 participants
n=206 Participants
260 participants
n=7 Participants
Alcohol Consumption
Once Monthly or Less Often
67 participants
n=99 Participants
73 participants
n=107 Participants
51 participants
n=206 Participants
191 participants
n=7 Participants
Alcohol Consumption
Once a Week
23 participants
n=99 Participants
31 participants
n=107 Participants
29 participants
n=206 Participants
83 participants
n=7 Participants
Alcohol Consumption
2 to 6 Times per Week
15 participants
n=99 Participants
19 participants
n=107 Participants
24 participants
n=206 Participants
58 participants
n=7 Participants
Alcohol Consumption
Daily
4 participants
n=99 Participants
3 participants
n=107 Participants
3 participants
n=206 Participants
10 participants
n=7 Participants

PRIMARY outcome

Timeframe: Baseline and Week 8

Population: Full Analysis Set included all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy. Participants with scores of \> 70 at Baseline were excluded.

The DSST assesses relative contributions of speed, memory, executive function and visual scanning. Participants are required to copy symbols that are paired with simple geometric shapes or numbers within a specific time for a total possible score of 0 to 133. Higher scores-correct number of symbols reflects greater objective cognitive functioning. An increase in score represents an improvement in an integrated measure of cognitive function. An Analysis of Covariance (ANCOVA) model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=187 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=167 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the Digit Symbol Substitution Test (DSST)
4.60 Correct symbols
Standard Error 0.530
4.06 Correct symbols
Standard Error 0.511
2.85 Correct symbols
Standard Error 0.542

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy,with data available for analysis.

PDQ is a patient-rated scale designed to subjectively assess cognitive dysfunction, comprising four 5-item subscales: Attention/Concentration, Retrospective Memory, Prospective Memory, and Planning/Organization for a total possible score of 0 to 40. The subscale Attention/Concentration is the sum of items 1, 5, 9, 13, and 17 with a range of 0-20; while the subscale Planning/Organization is the sum of items 4, 8, 12, 16, and 20 with the score range of 0 to 20. The scores of the subscales Attention/Concentration and Planning/Organization were summed. Higher scores reflect greater participant-perceived cognitive dysfunction in the domains identified. A decrease in score represents an improvement in subjective cognitive function in the domains identified. A Mixed Model Repeated Measures (MMRM) model was used with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=169 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=179 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=160 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the Perceived Deficits Questionnaire (PDQ) Attention/Concentration and Planning/Organization Subscore
-8.9 score on a scale
Standard Error 0.55
-9.3 score on a scale
Standard Error 0.53
-6.3 score on a scale
Standard Error 0.57

SECONDARY outcome

Timeframe: Baseline, Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy, with data available for analysis.

The CGI-I assesses the clinician's impression of the subject's state of mental illness improvement and consists of one question for the investigator: "Compared to his condition at the start of the study, how much has this patient changed?" which is rated on a seven-point scale (1=very much improved; 2=much improved; 3=minimally improved; 4=no change relative to baseline; 5=minimally worse; 6= much worse; 7=very much worse). Higher scores indicate greater worsening of illness. Values closest to 1 for this outcome measure indicate the greatest improvement of symptoms. A MMRM model was used with baseline\*week, center, week, treatment and week\*treatment as factors in the analysis.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=169 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=179 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=161 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Clinical Global Impressions-Improvement (CGI-I) Score at Week 8
2.349 score on a scale
Standard Error 0.0852
2.235 score on a scale
Standard Error 0.0826
2.639 score on a scale
Standard Error 0.0872

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy, with data available for analysis.

The TMT is a two-part cognitive test. TMT-A assesses cognitive processing speed and consists of 25 circles distributed over a sheet of paper. Participants have 4 minutes to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Tester informs participant immediately whenever they make an error and allows for corrections by participants. Lower scores represent better speed of processing. A decrease in score over the study represents an improvement in speed in processing. An ANCOVA model was used with treatment and center as fixed factors and the baseline value as a covariate.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=173 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=180 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=162 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the Trail Making Test (TMT-A)
-7.70 seconds
Standard Error 0.980
-8.06 seconds
Standard Error 0.955
-6.65 seconds
Standard Error 1.009

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy, with data available for analysis.

The TMT is a two-part cognitive test. TMT-B assesses executive functioning and consists of 25 circles distributed over a sheet of paper. Participants have 4 minutes to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Tester informs participant immediately whenever they make an error and allows for corrections by participants. Lower score for TMT-B represents better executive function. A decrease in score over the study represents an improvement in executive function. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=157 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=170 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=157 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the Trail Making Test B (TMT-B)
-18.73 seconds
Standard Error 2.096
-14.60 seconds
Standard Error 2.011
-9.06 seconds
Standard Error 2.101

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy, with data available for analysis.

The STROOP test assesses the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises of 2 sheets with 50 words each, up to 50 correct responses for each of the congruent and incongruent Stroop tests. Participants have 4 minutes to name the ink color of each word. Lower time to complete the test indicates better performance. Higher number of correct responses indicates better responses. A decrease in the time to complete the tests and an increase in the number of correct responses both indicate improvement over the course of the study. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=187 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=167 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change in Time From Baseline to Week 8 in the Stroop Test
Congruent (n=174,187,167)
-3.30 seconds
Standard Deviation 1.086
-4.54 seconds
Standard Deviation 1.044
-4.37 seconds
Standard Deviation 1.105
Change in Time From Baseline to Week 8 in the Stroop Test
Incongruent (n=172,186,166)
-8.17 seconds
Standard Deviation 1.560
-9.83 seconds
Standard Deviation 1.498
-8.11 seconds
Standard Deviation 1.586

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy, with data available for analysis.

The GMLT measures executive functioning and spatial problem solving. Participants learn a hidden pathway through a maze of 10 x 10 grid of tiles on a computer touch screen using step-by-step guess, with trial and error feedback after each step. Once the pathway is learned, participants repeat the same pathway four more times. It usually takes 5-6 minutes to administer this test. Lower score equals better performance. A decrease in score over the course of the study indicates improved executive function. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=169 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=179 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=159 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the Groton Maze Learning Test (GMLT)
-5.43 Errors
Standard Error 1.355
-5.16 Errors
Standard Error 1.314
-3.49 Errors
Standard Error 1.397

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy, with data available for analysis.

The DT is a computerized test that measures simple reaction time and psychomotor speed. The task requires participants to respond by pressing a "yes" button as soon as an onscreen playing card is turned over and is red, and by pressing a "no" button if the card is not red. It takes 2 minutes to be administered. There is no minimum or maximum scores since it is a time-based assessment. Lower score equals better performance. A decrease in score over the course of the study indicates improved speed of processing and psychomotor function. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=182 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=167 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the Detection Task (DT)
-0.050 Log10 milliseconds
Standard Error 0.0080
-0.039 Log10 milliseconds
Standard Error 0.0078
-0.033 Log10 milliseconds
Standard Error 0.0082

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy, with data available for analysis.

The IT measured choice reaction time: the participant pressed a "yes" button whenever an onscreen playing card turned face up and was red, or a "no" button if the card was not red. The IT took on average 2 minutes to complete. Lower scores equal better performance. A decrease in score over the course of the study indicates improved visual attention/vigilance. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=182 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=167 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the Identification Task (IT)
-0.037 Log10 milliseconds
Standard Error 0.0060
-0.030 Log10 milliseconds
Standard Error 0.0059
-0.024 Log10 milliseconds
Standard Error 0.0062

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy, with data available for analysis.

The One-Back test measures the cognitive domain of attention and working memory through yes or no responses to 30 trials. The task requires participants to report when a stimulus item presented serially is the same as an item one step back from the item at hand for a total correct responses 0 to 100. It usually takes 2-3 minutes to be administered. Higher scores equal better performance. An increase in score over the course of the study indicates improved attention/working memory. An ANCOVA model was used with treatment and center as fixed factors and the Baseline value as a covariate.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=182 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=167 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the One-Back Task
-0.028 Log 10 milliseconds
Standard Error 0.0062
-0.024 Log 10 milliseconds
Standard Error 0.0060
-0.022 Log 10 milliseconds
Standard Error 0.0063

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Full Analysis Set included all participants who were randomized, received at least 1 dose of study drug, and had at least 1 valid post-baseline value for assessment.

Improvement of Cognitive Dysfunction is determined using the change from Baseline to Week 8 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score and the Digital Symbol Substitution Test (DSST) total number of correct symbols. The MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression). The DSST assesses relative contributions of speed, memory, executive function and visual scanning. The proportion of direct effect from treatment = DSST difference / (DSST difference + coefficient\*MADRS difference).

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=187 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Proportion of Cognitive Dysfunction Improvement Due to Improvement of Depression
75.66 proportion of direct effect
48.69 proportion of direct effect

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 4 and Week 8

Population: Full Analysis Set included all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy. Last Observation Carried Forward.

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. A negative change from Baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=187 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=167 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the MADRS Total Score
Change at Week 1
-3.7 score on a scale
Standard Deviation 4.80
-4.6 score on a scale
Standard Deviation 5.29
-3.4 score on a scale
Standard Deviation 5.03
Change From Baseline to Week 8 in the MADRS Total Score
Change at Week 4
-9.8 score on a scale
Standard Deviation 6.85
-11.6 score on a scale
Standard Deviation 7.94
-8.0 score on a scale
Standard Deviation 7.98
Change From Baseline to Week 8 in the MADRS Total Score
Change at Week 8
-14.3 score on a scale
Standard Deviation 8.97
-15.5 score on a scale
Standard Deviation 9.23
-12.3 score on a scale
Standard Deviation 9.64

SECONDARY outcome

Timeframe: Baseline and Week 8

Population: Full Analysis Set included all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy. Last Observation Carried Forward.

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. MADRS Response was defined as a ≥50% decrease in MADRS Total Score from Baseline.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=187 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=167 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Percentage of Participants With MADRS Response at Week 8
50.9 percentage of participants
54.5 percentage of participants
41.3 percentage of participants

SECONDARY outcome

Timeframe: Week 8

Population: Full Analysis Set included all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy. Last Observation Carried Forward.

MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (such as apparent sadness, reported sadness, inner tension) rated on a 7-point Likert scale from 0 (symptoms absent) to 6 (severe depression) with a total possible score range from 0 to 60. Higher scores indicate greater severity of symptoms. MADRS Remission was defined as a MADRS total score ≤10.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=187 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=167 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Percentage of Participants in MADRS Remission at Week 8
30.3 percentage of participants
33.7 percentage of participants
21.6 percentage of participants

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 4 and Week 8

Population: Participants from the Full Analysis Set, all randomized participants who received at least one dose of study drug and had at least 1 valid post-baseline value for assessment of primary efficacy,with data available for analysis. Repeated Measures Analysis.

The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill). A MMRM model with baseline\*week, center, week, treatment and week\*treatment as factors was used for analyses.

Outcome measures

Outcome measures
Measure
Vortioxetine (Lu AA21004)
n=175 Participants
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=187 Participants
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=167 Participants
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score
Change from Baseline at Week 1 (n=174, 187,167)
-0.289 score on a scale
Standard Error 0.0426
-0.353 score on a scale
Standard Error 0.0410
-0.243 score on a scale
Standard Error 0.0435
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score
Change from Baseline at Week 4 (n=173,184,165)
-0.951 score on a scale
Standard Error 0.0678
-1.170 score on a scale
Standard Error 0.0656
-0.617 score on a scale
Standard Error 0.0693
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity (CGI-S) Score
Change from Baseline at Week 8 (n=169,179,161)
-1.546 score on a scale
Standard Error 0.0886
-1.698 score on a scale
Standard Error 0.0859
-1.225 score on a scale
Standard Error 0.0906

Adverse Events

Vortioxetine (Lu AA21004)

Serious events: 1 serious events
Other events: 73 other events
Deaths: 0 deaths

Duloxetine

Serious events: 1 serious events
Other events: 84 other events
Deaths: 0 deaths

Placebo

Serious events: 2 serious events
Other events: 41 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Vortioxetine (Lu AA21004)
n=196 participants at risk
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=207 participants at risk
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=191 participants at risk
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Cardiac disorders
Acute myocardial infarction
0.00%
0/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.00%
0/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.52%
1/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Injury, poisoning and procedural complications
Craniocerebral injury
0.00%
0/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.48%
1/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.00%
0/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Injury, poisoning and procedural complications
Subdural haematoma
0.00%
0/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.48%
1/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.00%
0/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Psychiatric disorders
Depression
0.00%
0/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.00%
0/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.52%
1/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Psychiatric disorders
Suicide attempt
0.51%
1/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.00%
0/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.00%
0/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.

Other adverse events

Other adverse events
Measure
Vortioxetine (Lu AA21004)
n=196 participants at risk
Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
Duloxetine
n=207 participants at risk
Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
Placebo
n=191 participants at risk
Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
Gastrointestinal disorders
Nausea
20.4%
40/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
20.8%
43/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
4.2%
8/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Gastrointestinal disorders
Diarrhoea
5.6%
11/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
2.9%
6/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
2.6%
5/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Gastrointestinal disorders
Dry mouth
3.1%
6/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
7.7%
16/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
4.7%
9/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Infections and infestations
Nasopharyngitis
3.6%
7/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
3.9%
8/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
5.8%
11/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Metabolism and nutrition disorders
Decreased appetite
1.5%
3/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
5.8%
12/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
0.52%
1/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Nervous system disorders
Headache
10.2%
20/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
11.6%
24/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
8.4%
16/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Nervous system disorders
Dizziness
3.1%
6/196 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
5.3%
11/207 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
2.6%
5/191 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Up to 12 Weeks)
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.

Additional Information

Medical Director

Takeda

Phone: +1-877-825-3327

Results disclosure agreements

  • Principal investigator is a sponsor employee The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.
  • Publication restrictions are in place

Restriction type: OTHER